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the 1975 Declaration of Helsinki and was ap‑
proved by the institutional ethics committee. 
Informed consent was obtained from each study 
participant.
Results and discussion We enrolled 50 pa‑
tients with PAH (n = 31; 62% women) at the 
median (IQR) age of 57 (45.5–71) years, with 
idiopathic PAH (n = 40 [80%]) and PAH asso‑
ciated with connective tissue disease (n = 10 
[20%]). At the time of enrollment, most patients 
(n = 45 [90%]) had been previously diagnosed 
and 5 (10%) patients were newly diagnosed.
At enrollment, half of the patients presented 
with the World Health Organization function‑
al class (WHO ‑FC) III (n = 25 [50%]) followed 
by WHO ‑FC II (n = 22 [44%]), IV (n = 2 [4%]), 
and I (n = 1 [2%]). Our study protocol and main 
findings are presented in Figure 1.
The most common first symptoms of PAH in‑
cluded dyspnea (n = 38 [76%]), tiredness (n = 37 
[74%]), and fatigue (n = 35 [70%]). Other initial 
manifestations reported by patients are listed 
in Supplementary material, Figure S1. The medi‑
an (IQR) number of symptoms reported by each 
patient was 3 (2–5).
More than half of the respondents (n = 26 
[52%]) reported that their first symptoms were 
mild (WHO ‑FC II). The others reported symp‑
toms typical of WHO ‑FC I (n = 5 [10%]), III 
(n = 17 [34%]), and IV (n = 2 [4%]).
Most patients reported their first symptoms to 
general practitioners (GPs; n = 25 [50%]), followed 
by cardiologists (n = 8 [16%]), or other specialists 
(n = 4 [8%]) including: 1 pulmonologist, 1 rheuma‑
tologist, and 2 physicians without specialization; 
Introduction Pulmonary arterial hyperten‑
sion (PAH) is a severe, progressive disease with 
poor prognosis.1‑3 Early recognition of symp‑
toms and prompt diagnosis facilitate intro‑
duction of PAH ‑specific treatment at earlier 
stages of the disease, which results in better 
prognosis.4‑7
According to the Polish registry of pulmo‑
nary hypertension (PH), as many as 5.2 new 
cases of PAH patients per million adults are di‑
agnosed every year,8,9 and the mean (SD) time 
from the onset of symptoms to the first medical 
contact (FMC) is estimated at 9.6 (27.3) months. 
Still, the diagnostic pathway of the patient from 
the time of first symptoms to the time of FMC 
and the time of the final diagnosis at the ref‑
erence center remains unknown. Therefore, 
we aimed to characterize the critical steps in 
the diagnostic process of PAH and to determine 
potential causes of delay in PAH diagnosis in 
a sample of Polish patients with PAH.
Methods We enrolled consecutive patients 
with PAH10 who underwent routine assess‑
ment in a PH referral center for adults between 
March 1, 2019 and May 1, 2019 and agreed to 
participate in the study. We excluded patients 
with PAH resulting from congenital heart dis‑
eases, as they usually had their diagnosis es‑
tablished in childhood. We performed a pre‑
specified interview with each patient. Data 
were presented as the number (percentage) or 
median (interquartile range [IQR]). A detailed 
description of the study methods is present‑
ed in Supplementary material. The study pro‑
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diagnosis of PH, patients underwent a median 
(IQR) number of 3 (2–4) medical consultations. 
The initial diagnosis was made most frequent‑
ly by cardiologists (n = 40 [80%]). The median 
(IQR) time between the initial and final diag‑
nosis established in the PH reference center 
was 2.5 (1–4) months.
At the time of the initial diagnosis of PH, a half 
of the study patients (n = 25 [50%]) manifest‑
ed exertional dyspnea at WHO ‑FC III, 14 (28%) 
at WHO ‑FC IV, and 8 (16%) at WHO ‑FC II. Three 
patients (6%) could not provide this information.
The median (IQR) time between first symp‑
toms and the final diagnosis of PAH was 18 (9–29) 
months. During that time, patients reported pro‑
gression of dyspnea from WHO ‑FC I / II (n = 31 
[52%]) to WHO ‑FC III / IV (n = 46 [92%]; P <0.001).
We showed that the median time between 
first symptoms and the final diagnosis of PAH 
was 18 months. Consequently, at PAH diagnosis, 
most patients presented with severe symptoms. 
The diagnostic delay was related to both patient ‑ 
and healthcare ‑dependent factors.
Pulmonary arterial hypertension is a severe 
disease with very short survival in its natural 
history of approximately 2.8 years.11 Therefore, 
of importance are the results of our study, which 
quantify the diagnostic delay in Polish patients 
with PAH and provide insight into the causes 
underlying this finding. The median time from 
the onset of symptoms to PAH diagnosis is com‑
parable to that presented in some American re‑
ports5,12 and shorter than observed in other stud‑
ies from France (2.3 years), Germany (2.3 years), 
6 patients (12%) presented to the emergency de‑
partment because of progressing exertional dys‑
pnea; 7 patients (14%) could not provide this in‑
formation. At the time of FMC, half of the pa‑
tients (n = 25 [50%]) were in WHO ‑FC III, 8 (16%) 
in WHO ‑FC IV, 3 (6%) in WHO ‑FC II, and a sin‑
gle patient (2%) was in WHO ‑FC I. Thirteen pa‑
tients (26%) were unable to describe the severi‑
ty of symptoms at that point.
The  median (IQR) time between the  first 
manifestation(s) and FMC (patient ‑related de‑
lay) was 3 (1–12) months. Almost half of the pa‑
tients (n = 23 [46%]) did not initially (within 
a week) visit the doctor when the first symp‑
toms appeared. The most commonly indicated 
reasons for patient ‑related delay were only slight 
limitation of physical activity (n = 19 [38%]), ex‑
pected remission of symptoms (n = 15 [30%]), 
and ascribing the symptoms to other disorders 
(n = 6 [12%]).
Conditions that prompted patients to vis‑
it a physician were disease progression (n = 20 
[40%]), persistence (n = 10 [20%]), and occur‑
rence of new symptoms (n = 9 [18%]). In the re‑
gression model including patient ‑related delay 
as a dependent variable and the number of ini‑
tial symptoms, age, urban versus rural residence, 
education level, and number of comorbidities 
as independent variables, only the number of 
initial symptoms (β = –2.84; r = –0.38; P = 0.01) 
predicted the time from symptom onset to FMC.
The median (IQR) time of healthcare ‑related 
delay (the time from FMC to PAH diagnosis) 
was 7 (4–17) months. Before getting the initial 











Total median (IQR) delay,a 18 (9–29) months
FIRST SYMPTOMS:
• 76% – dyspnea
• 74% – tiredness
• 70% – fatigue
• 22% – chest pain
FIRST MEDICAL CONTACT:
• 50% – general practitioner
• 16% – cardiologist
• 12% – emergency department
• 22% – other / did not remember
SUSPICION OF PH:
• 80% – cardiologist
• 4% – general practitioner
• 16% – other / did not   
   remember
FINAL DIAGNOSIS:
Significant increase in WHO-FC
Patient-related delayb: 3 months
 • 46% of patients did not 
   initially visit the doctor at  
   the time of first symptom onset
Healthcare-related delayc: 7 months 

























and Australia (3.9 years).13‑15 These studies were, 
however, performed, on average, a decade ago 
and it is possible that awareness of PH was low‑
er at that time.
The time to the final diagnosis in our study was 
longer than that recently presented by the authors of 
the Polish registry of PAH (BNP ‑PL); however, only 
incident patients were analyzed in that registry.8
On their way to the final diagnosis of PAH, 
our patients underwent a median number of 
3 medical consultations which did not result in 
the proper diagnosis. In an Australian study, pa‑
tients reported a mean number of 5.3 GP visits 
and 3 specialist visits,13 whereas 54% of the pa‑
tients underwent at least 3 medical consulta‑
tions according to a German study.14 These data 
suggest that there is insufficient awareness of 
PAH among GPs and specialists.
In our study, no single symptom was associ‑
ated with a shorter pathway to PAH diagnosis. 
This was also highlighted in other studies and as‑
cribed to a nonspecific nature of PAH symptoms 
resulting in their misinterpretation. We found 
that only the number of symptoms correlated 
with the time to the final diagnosis.
We concluded that the time to the final diag‑
nosis is significantly prolonged in Polish patients 
with PAH owing to both patient‑ and healthcare‑
‑related factors. Therefore, further effort is need‑
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